Evidence map›Paper›PMID 41999653›Full record

ArticleImmunoHorizons2026

ZBP1 mediated restriction of Toxoplasma gondii in both the early acute and chronic brain stages of infection.

Lydia Anne Sibley, Isaac William Babcock, Naa Dedee Amadi, Anne Elise Marchildon, Abigail Grace Kelly, Sydney Ann Labuzan, John Robert Lukens, Tajie Heartsong Harris

Abstract read
In one paragraph

Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lydia Anne SibleyCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.
Isaac William BabcockCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.
Naa Dedee AmadiCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.
Anne Elise MarchildonCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.
Abigail Grace KellyCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.
Sydney Ann LabuzanCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.
John Robert LukensCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.
Tajie Heartsong HarrisCenter for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, VA, United States.ORCID 0000-0002-1355-2109

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Biotechnology Training ProgramT32GM136615 · NIGMS · UNIVERSITY OF VIRGINIA · PI Silvia Salinas Blemker, Kimberly A. Kelly · 2020 to 2026
$3.4M
Alarmin-mediated control of CNS infectionR01NS112516 · NINDS · UNIVERSITY OF VIRGINIA · PI HARRIS, TAJIE H. · 2020 to 2023
$1.9M
Caspase-8 mediated control of CNS infectionR01NS134747 · NINDS · UNIVERSITY OF VIRGINIA · PI TAJIE H. HARRIS · 2024 to 2026
$1.5M
Brain, Immunology and Glia Training ProgramT32NS115657 · NINDS · UNIVERSITY OF VIRGINIA · PI Alban P Gaultier, TAJIE H. HARRIS · 2021 to 2026
$1.2M
NIAID NIH HHS T32 AI007496NIGMS NIH HHS T32 GM007267NIGMS NIH HHS T32 GM136615NIH HHS R01NS112516NINDS NIH HHS R01 NS112516NINDS NIH HHS R01 NS134747NINDS NIH HHS T32 NS115657
6 · The paper itself

Abstract

ZBP1 is an innate sensor of nucleic acids in the Z-conformation and regulates immune responses via cell death pathways and nuclear factor κB signaling. Previous work has demonstrated an essential role for ZBP1 in viral restriction; however, the role ZBP1 plays in protection against other pathogens is in early stages of exploration. Toxoplasma gondii is an obligate intracellular parasite that can infect all nucleated cells and establishes a chronic infection of the brain requiring a robust innate and adaptive immune response and multiple cell death pathways for host survival. Importantly, innate sensors of T. gondii infection of the central nervous system are still being defined. Prior work has implicated caspase-1 and caspase-8 in the control of T. gondii in the brain. Because ZBP1 can activate both caspase-1 and caspase-8, we sought to explore the role of ZBP1 during T. gondii infection. During early infection, we found an increase in parasite burden; a decrease in NK1.1+ cell, neutrophil, and monocyte recruitment; and impaired NK1.1+ cell cytokine production in the peritoneum of Zbp1-/- mice. Interestingly, during the early adaptive immune response, the immune cell recruitment defects and impaired parasite control were ameliorated. During the brain stage of infection, ZBP1 regulated parasite restriction and numerous inflammatory responses to infection. Our findings establish ZBP1 as a critical regulator of host defense to T. gondii and highlight the importance of ZBP1 in development of inflammation during both the acute and chronic infection.

Indexed as

BrainRNA-Binding ProteinsToxoplasmaToxoplasmosisToxoplasmosis, AnimalAnimalsChronic DiseaseCytokinesFemaleImmunity, InnateMiceMice, Inbred C57BLMice, KnockoutCytokinesRNA-Binding ProteinsZbp1 protein, mouseneuroinflammationToxoplasma gondiiZBP1

Identifiers

PMID41999653
PMCPMC13091654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.